171 related articles for article (PubMed ID: 393427)
21. Synthesis and biological evaluation of S-acyl-3-thiopropyl prodrugs of N-phosphonoacetyl-L-aspartate (PALA).
Gagnard V; Leydet A; Le Mellay V; Aubenque M; Morère A; Montero JL
Eur J Med Chem; 2003 Oct; 38(10):883-91. PubMed ID: 14575935
[TBL] [Abstract][Full Text] [Related]
22. Antiproliferative agents and differential survival between normal and cancer cells.
Tsuboi KK; Kwong LK
Cancer Res; 1978 Nov; 38(11 Pt 1):3745-50. PubMed ID: 698934
[TBL] [Abstract][Full Text] [Related]
23. Differential effect of N-(phosphonacetyl)-L-aspartate on 1-beta-D-arabinofuranosylcytosine metabolism and cytotoxicity in human leukemia and normal bone marrow progenitors.
Grant S; Rauscher F; Cadman E
Cancer Res; 1982 Oct; 42(10):4007-13. PubMed ID: 6955007
[TBL] [Abstract][Full Text] [Related]
24. Biochemical interactions between N-(phosphonacetyl)-L-aspartate and 5-fluorouracil.
Liang CM; Donehower RC; Chabner BA
Mol Pharmacol; 1982 Jan; 21(1):224-30. PubMed ID: 6813676
[No Abstract] [Full Text] [Related]
25. Modulation of human ovarian tumor cell sensitivity to N-(phosphonacetyl)-L-aspartate (PALA) by liposome drug carriers.
Sharma A; Straubinger NL; Straubinger RM
Pharm Res; 1993 Oct; 10(10):1434-41. PubMed ID: 8272404
[TBL] [Abstract][Full Text] [Related]
26. Biochemistry and clinical activity of N-(phosphonacetyl)-L-aspartate: a review.
Grem JL; King SA; O'Dwyer PJ; Leyland-Jones B
Cancer Res; 1988 Aug; 48(16):4441-54. PubMed ID: 3293772
[No Abstract] [Full Text] [Related]
27. N-(Phosphonoacetyl)amino phosphonates. Phosphonate analogues of N-(phosphonoacetyl)-L-aspartic acid (PALA).
Kafarski P; Lejczak B; Mastalerz P; Duś D; Radzikowski C
J Med Chem; 1985 Nov; 28(11):1555-8. PubMed ID: 4067984
[TBL] [Abstract][Full Text] [Related]
28. N-(phosphonacetyl)-L-aspartate synergistically enhances the cytotoxicity of 5-fluorouracil/interferon-alpha-2a against human colon cancer cell lines.
Wadler S; Mao X; Bajaj R; Hallam S; Schwartz EL
Mol Pharmacol; 1993 Nov; 44(5):1070-6. PubMed ID: 8246910
[TBL] [Abstract][Full Text] [Related]
29. Comparative physiological disposition of N-(phosphonacetyl)-L-aspartate in several animal species after intravenous and oral administration.
Chadwick M; Silveira DM; MacGregor JA; Branfman AR; Liss RH; Yesair DW
Cancer Res; 1982 Feb; 42(2):627-32. PubMed ID: 7055806
[TBL] [Abstract][Full Text] [Related]
30. Kinetics of the interaction of N-(phosphonacetyl)-L-aspartate with the catalytic subunit of aspartate transcarbamoylase. A slow conformational change subsequent to binding.
Cohen RE; Schachman HK
J Biol Chem; 1986 Feb; 261(6):2623-31. PubMed ID: 3949739
[TBL] [Abstract][Full Text] [Related]
31. Effects of acivicin and PALA, singly and in combination, on de novo pyrimidine biosynthesis.
Kensler TW; Jayaram HN; Cooney DA
Adv Enzyme Regul; 1982; 20():57-73. PubMed ID: 7113804
[TBL] [Abstract][Full Text] [Related]
32. Role of endocytosis and lysosomal pH in uptake of N-(phosphonacetyl)-L-aspartate and its inhibition of pyrimidine synthesis.
White JC; Hines LH
Cancer Res; 1984 Feb; 44(2):507-13. PubMed ID: 6692357
[TBL] [Abstract][Full Text] [Related]
33. Binding of radiolabeled N-(phosphonacetyl)-L-aspartate to aspartate transcarbamylase from Ehrlich ascites tumor cells.
White JC; Hines LH
Biochem Pharmacol; 1984 Nov; 33(22):3645-8. PubMed ID: 6508821
[TBL] [Abstract][Full Text] [Related]
34. m-AMSA: a new anticancer agent.
Rozencweig M; Von Hoff DD; Legha SS; Cysyk RL; Muggia FM
Recent Results Cancer Res; 1980; 74():250-7. PubMed ID: 6893753
[TBL] [Abstract][Full Text] [Related]
35. The role of low-dose PALA in biochemical modulation.
O'Dwyer PJ
Pharmacol Ther; 1990; 48(3):371-80. PubMed ID: 2084707
[TBL] [Abstract][Full Text] [Related]
36. Kinetics of N-(phosphonacetyl)-L-aspartate and pyrazofurin depletion of pyrimidine ribonucleotide and deoxyribonucleotide pools and their relationship to nucleic acid synthesis in intact and permeabilized cells.
Moyer JD; Smith PA; Levy EJ; Handschumacher RE
Cancer Res; 1982 Nov; 42(11):4525-31. PubMed ID: 7127293
[TBL] [Abstract][Full Text] [Related]
37. An enzymatic technique for measuring N-phosphonacetyl-L-aspartic acid in tissues.
Cooney DA; Karlowicz MG; Cubillan J; Roettger M; Jayaram HN
Cancer Treat Rep; 1978 Oct; 62(10):1503-7. PubMed ID: 361225
[TBL] [Abstract][Full Text] [Related]
38. Gene amplification causes overproduction of the first three enzymes of UMP synthesis in N-(phosphonacetyl)-L-aspartate-resistant hamster cells.
Wahl GM; Padgett RA; Stark GR
J Biol Chem; 1979 Sep; 254(17):8679-89. PubMed ID: 381311
[TBL] [Abstract][Full Text] [Related]
39. Phase II study of PALA and AMSA in advanced renal cell carcinoma.
Earhart RH; Elson PJ; Rosenthal SN; Hahn RG; Slayton RE
Am J Clin Oncol; 1983 Oct; 6(5):555-60. PubMed ID: 6688498
[TBL] [Abstract][Full Text] [Related]
40. Quantitation of the antitumor agent N-(phosphonacetyl)-L-aspartic acid in human plasma and urine by gas chromatography-mass spectrometry-selected ion monitoring.
Branfman AR; Bruni RJ; Merrill YN; Chadwick M; Strong JM; Ervin TJ
J Chromatogr; 1980 May; 182(2):163-9. PubMed ID: 7380909
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
